Department of MRI, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China; Functional Magnetic Resonance and Molecular Imaging Key Laboratory of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
Department of MRI, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
Acta Biomater. 2023 Mar 1;158:571-582. doi: 10.1016/j.actbio.2022.12.053. Epub 2022 Dec 28.
Image-guided stimulus-responsive theranostics are beneficial for identifying malignant lesions and integrating multiple cell-killing mechanisms to enhance tumor cell clearance. Herein, an intelligent dual-responsive nanostructure (HSPMH-DOX) was developed for magnetic resonance imaging (MRI)-guided synergistic chemo-photothermal therapy (PTT) and chemodynamic therapy (CDT). The core-shell nanostructure was synthesized by layering polydopamine (PDA), manganese oxide (MnO), and hyaluronic acid (HA) onto drug-loaded hollow mesoporous silica nanoparticles (HS). The constructed nanoagent has both endogenous and external dual responses. The tumor microenvironment (pH/GSH) can trigger the degradation of gatekeeper (MnO and PDA), resulting in the release of anti-tumor drugs, whereas external near-infrared light irradiation can accelerate the degradation process and generate local overheating, resulting in PTT. Notably, MnO can not only consume intracellular GSH to enhance CDT but also release Mn for precise localization of tumor tissues using MRI. Both in vitro and in vivo experiments showed that the prepared dual-response nanoagent satisfied biocompatibility, targeting, and the great efficiency of MRI-guided combined therapy. In animal models, combining chemo-PTT and CDT can eradicate tumors in less than two weeks. This work could pave the way for a wide range of stimulus-responsive synergistic theranostic applications, including MRI, chemo-photothermal therapy, and chemodynmic therapy. STATEMENT OF SIGNIFICANCE: Low bioavailability and severe side effects remain the major limitations of conventional cancer chemotherapy. Image-guided combination therapy can alleviate these problems and improve tumor-specific therapy. In the present study, the anticancer drug doxorubicin was encapsulated in a core-shell hollow mesoporous silica nanostructure (HSPMH-DOX), enabling MRI-guided targeted release under both endogenous and external dual stimuli. Moreover, the photothermal and nanoenzymatic effects of nanomedicine can cause local overheating in the tumor and amplify the intracellular CDT effect, accelerating tumor eradication. Systematic evaluations in vitro and in vivo confirmed that nanomedicine enables highly effective MRI-guided synergistic chemo-photothermal and chemodynamic therapy. This work offers a promising therapeutic strategy for precise anti-tumor applications.
基于图像引导的刺激响应型治疗在识别恶性病变和整合多种细胞杀伤机制以增强肿瘤细胞清除方面具有优势。在此,开发了一种智能双响应纳米结构(HSPMH-DOX),用于磁共振成像(MRI)引导的协同化学-光热治疗(PTT)和化学动力学治疗(CDT)。核壳纳米结构是通过将聚多巴胺(PDA)、氧化锰(MnO)和透明质酸(HA)分层到载药的中空介孔硅纳米颗粒(HS)上合成的。构建的纳米剂具有内源性和外源性双重响应。肿瘤微环境(pH/GSH)可以触发门控(MnO 和 PDA)的降解,导致抗肿瘤药物的释放,而外部近红外光照射可以加速降解过程并产生局部过热,从而实现 PTT。值得注意的是,MnO 不仅可以消耗细胞内的 GSH 来增强 CDT,还可以释放 Mn 用于 MRI 对肿瘤组织的精确定位。体外和体内实验均表明,所制备的双响应纳米剂具有良好的生物相容性、靶向性和 MRI 引导的联合治疗的高效性。在动物模型中,联合化疗-PTT 和 CDT 可以在不到两周的时间内消灭肿瘤。这项工作为广泛的刺激响应型协同治疗应用铺平了道路,包括 MRI、化学-光热治疗和化学动力学治疗。意义声明:传统癌症化疗的生物利用度低和严重的副作用仍然是主要限制。图像引导的联合治疗可以缓解这些问题并提高肿瘤特异性治疗效果。在本研究中,阿霉素被包裹在核壳中空介孔硅纳米结构(HSPMH-DOX)中,使其能够在内外双重刺激下进行 MRI 引导的靶向释放。此外,纳米药物的光热和纳米酶效应可以导致肿瘤局部过热,并放大细胞内 CDT 效应,加速肿瘤清除。体外和体内的系统评估证实,纳米药物能够实现高效的 MRI 引导的协同化学-光热和化学动力学治疗。这项工作为精确抗肿瘤应用提供了一种有前途的治疗策略。
Colloids Surf B Biointerfaces. 2022-10
Int J Nanomedicine. 2025-8-29
J Funct Biomater. 2025-7-2
J Nanobiotechnology. 2024-11-4
Int J Nanomedicine. 2024
J Nanobiotechnology. 2024-6-15
Exploration (Beijing). 2023-10-17